Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

ClinicalTrials.gov ID: NCT01313637

Public ClinicalTrials.gov record NCT01313637. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 20, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 Inhalation Powder and the Individual Components Delivered Once-Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease

Study identification

NCT ID
NCT01313637
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
1,493 participants

Conditions and interventions

Interventions

  • GSK573719/GW642444 125/25mcg Drug
  • GSK573719 125mcg Drug
  • GW642444 25mcg Drug
  • Placebo only Drug

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2011
Primary completion
Feb 29, 2012
Completion
Apr 18, 2012
Last update posted
Jan 28, 2018

2011 – 2012

United States locations

U.S. sites
24
U.S. states
12
U.S. cities
23
Facility City State ZIP Site status
GSK Investigational Site Jasper Alabama 35501
GSK Investigational Site Phoenix Arizona 85006
GSK Investigational Site Long Beach California 90822
GSK Investigational Site Los Angeles California 90095
GSK Investigational Site Palo Alto California 94304
GSK Investigational Site Riverside California 92506
GSK Investigational Site San Diego California 92103-8415
GSK Investigational Site San Diego California 92117
GSK Investigational Site Torrance California 90502
GSK Investigational Site Clearwater Florida 33765
GSK Investigational Site DeLand Florida 32720
GSK Investigational Site Orlando Florida 32822
GSK Investigational Site Panama City Florida 32405
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Livonia Michigan 48152
GSK Investigational Site Plymouth Minnesota 55441
GSK Investigational Site Lincoln Nebraska 68506
GSK Investigational Site Cherry Hill New Jersey 08003
GSK Investigational Site Charlotte North Carolina 28207
GSK Investigational Site Easley South Carolina 29640
GSK Investigational Site Greenville South Carolina 29615
GSK Investigational Site Spartanburg South Carolina 29303
GSK Investigational Site Union South Carolina 29379
GSK Investigational Site Richmond Virginia 23225

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 133 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01313637, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 28, 2018 · Synced Jul 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01313637 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →